VivoSeq
Gastroenterology

Chronic Gastritis

15

Pipeline Programs↗

0

Active Trials↗

10

Companies Involved↗

Chronic Gastritis is an emerging landscape with 15 programs across 10 companies. The most active players are Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical Company Limited, Daewon Pharmaceutical Co., Ltd.. 2 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 2Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

4 programs

Phase 3Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.

2 programs

Phase 3R

Respirent Pharmaceuticals Co Ltd.

2 programs

Phase 3Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 3Otsuka logo

Otsuka

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed11 · 100%

Clinical Trials

Trial Activity

11 trials

A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
Completed·DDong-A ST Co., Ltd.·Phase 2·NCT07139886·212 enrolled
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
Completed·Daewon Pharmaceutical Co., Ltd. logoDaewon Pharmaceutical Co., Ltd.·Phase 3·NCT05163756·332 enrolled
Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
Completed·Eisai logoEisai·Phase 4·NCT01190657·1,184 enrolled
To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
Completed·Daewon Pharmaceutical Co., Ltd. logoDaewon Pharmaceutical Co., Ltd.·Phase 3·NCT03443804·462 enrolled
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Completed·DDong-A ST Co., Ltd.·Phase 3·NCT06151210·467 enrolled
Clinical Effect of Rebamipide on Chronic Gastritis
Completed·—·Phase 4·NCT02393430·180 enrolled
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
Completed·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 3·NCT04341454·327 enrolled
Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 3·NCT05024721·326 enrolled
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
Completed·PPT Otsuka Indonesia·Phase 3·NCT00996788·55 enrolled
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT01119768·305 enrolled
Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis
Completed·SSK Chemicals Co., Ltd.·Phase 2·NCT01578811·102 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)